Search Results - EGA European Genome-Phenome Archive

Ancestry and somatic profile predict acral melanoma origin and prognosis – WXS

Acral melanoma, which is not ultraviolet (UV)-associated, is the most common type of melanoma in several low- and middle-income countries including Mexico. Latin American samples are significantly underrepresented in global cancer genomics studies, which directly affects patients in these regions as it is known that cancer risk and incidence may be influenced by ancestry and environmental exposures. To address this, we characterise the genome and transcriptome of 123 acral melanoma tumours from 92 Mexican patients, a population notable because of its genetic admixture. Compared with other studies of melanoma, we found fewer frequent mutations in classical driver genes such as BRAF, NRAS or NF1. While most patients had predominantly Amerindian genetic ancestry, those with higher European ancestry had increased frequency of BRAF mutations and a lower median number of structural variants. The tumours with activating BRAF mutations have a transcriptional profile more similar to cutaneous non-volar melanocytes, suggesting that acral melanomas in these patients may arise from a distinct cell of origin compared to other tumours arising in these locations. KIT mutations were found in a subset of these tumours, and quadruple wild-type samples (non BRAF/NRAS/NF1/KIT) differed from mutated samples in their structural genomic profile and overall and recurrence-free survival patterns. Transcriptional profiling defined three expression clusters; these characteristics were associated with recurrence-free and overall survival. We highlight potential novel low-frequency drivers, such as PTPRJ, NF2 and RDH5. Our study enhances knowledge of this understudied disease and underscores the importance of including samples from diverse ancestries in cancer genomics studies.

Dataset EGAD00001015755

Ancestry and somatic profile predict acral melanoma origin and prognosis – RNA

Acral melanoma, which is not ultraviolet (UV)-associated, is the most common type of melanoma in several low- and middle-income countries including Mexico. Latin American samples are significantly underrepresented in global cancer genomics studies, which directly affects patients in these regions as it is known that cancer risk and incidence may be influenced by ancestry and environmental exposures. To address this, we characterise the genome and transcriptome of 123 acral melanoma tumours from 92 Mexican patients, a population notable because of its genetic admixture. Compared with other studies of melanoma, we found fewer frequent mutations in classical driver genes such as BRAF, NRAS or NF1. While most patients had predominantly Amerindian genetic ancestry, those with higher European ancestry had increased frequency of BRAF mutations and a lower median number of structural variants. The tumours with activating BRAF mutations have a transcriptional profile more similar to cutaneous non-volar melanocytes, suggesting that acral melanomas in these patients may arise from a distinct cell of origin compared to other tumours arising in these locations. KIT mutations were found in a subset of these tumours, and quadruple wild-type samples (non BRAF/NRAS/NF1/KIT) differed from mutated samples in their structural genomic profile and overall and recurrence-free survival patterns. Transcriptional profiling defined three expression clusters; these characteristics were associated with recurrence-free and overall survival. We highlight potential novel low-frequency drivers, such as PTPRJ, NF2 and RDH5. Our study enhances knowledge of this understudied disease and underscores the importance of including samples from diverse ancestries in cancer genomics studies.

Dataset EGAD00001015756

Genomics Define Malignant Transformation in Myeloma Precursor Conditions

Multiple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). While these precursor conditions are asymptomatic, they are not entirely benign and carry a lifelong risk of progression to MM. Unlike other cancers defined by pathology, malignant transformation from MGUS or SMM to MM has so far relied on demonstration of clinical end-organ damage as morphology and cytogenetics cannot reliably distinguish them. In this study, using genomic data from 374 patients with MGUS or SMM (277 training, 97 validation), to our knowledge, we demonstrate for the first time the ability to identify malignant transformation in MGUS and SMM. We introduce the concept of genomic MM and genomic MGUS to differentiate the subsets of MGUS and SMM that are biologically malignant with genomic features indistinguishable from MM from the subset that is premalignant and unlikely to progress to malignancy. Importantly, we find that most SMM has biological features of malignant transformation indistinguishable from MM. As expected, this subset that we consider having genomic MM is associated with a high risk of progression to MM although some patients remained progression-free beyond 5 years. Conversely, 60% of MGUS and 10% of SMM have no evidence of malignant transformation (genomic MGUS), with no progression during follow-up. Integration of genomic features with the 2/20/20 International Myeloma Working Group model significantly improved the prediction of progression among genomic MM. These findings support the use of genomic criteria to refine the classification and the risk stratification in myeloma precursor conditions.

Dataset EGAD00001015768

CcRCC_metabolic_heterogeneity

Heterogeneity is a hallmark of clear cell renal cell carcinoma (ccRCC). In this study, hyperpolarized [1-13C]pyruvate MRI (HP-13C-MRI) was used to probe metabolic heterogeneity non-invasively in 6 ccRCC patients from which 58 tumor and healthy tissues biopsies were acquired postoperatively. MRI parameters were correlated with 146 metabolite concentrations and the expression of 2523 metabolic genes across 34 metabolic pathways. Using metabologram projections and pathway consensus scoring, several metabolic pathways were correlated with the metabolic MRI, including glycolysis, pentose phosphate pathway, and the TCA cycle. A simple thresholding approach applied to the imaging metrics was sufficient to provide meaningful metabolic pathway information. We also show that tissue metabolic heterogeneity increases in regions with higher pyruvate-to-lactate conversion on imaging. These results provide validation of the biological relevance of HP-13C-MRI and support the possibility of its clinical use to improve disease characterization, stratification, targeting of biopsies, and providing novel methods to monitor treatment response.

Dataset EGAD00001015780

A developmental cell atlas of the human thyroid gland

Thyroid hormones are essential for health, but human thyroid development and cellular heterogeneity are poorly understood. We generated a high-resolution, spatiotemporal transcriptional atlas of human fetal thyroid, and examined its perturbations in trisomy 21 (T21), where aberrant thyroid development is associated with congenital hypothyroidism, and in papillary thyroid carcinoma (PTC). Normal tissue revealed two functional follicular cell states (fTFC1, fTFC2) with divergent PAX8 expression levels, persisting into adulthood. Additionally, the rare C-cell population was comprehensively profiled at single-cell resolution for the first time. T21 fetal thyroid was hypoplastic, with disrupted follicular morphology and altered expression of genes mediating cellular topology and extracellular matrix interactions. Finally, the transcriptional signals of both fetal follicular cell states were found to be perturbed in PTC. Overall, we defined a reference atlas for normal human fetal thyrocyte heterogeneity and provided novel insights into thyroid disorders.

Dataset EGAD00001015783

5032 results for "*oma"

in 47.18 milliseconds.

Ancestry and somatic profile predict acral melanoma origin and prognosis – WXS

Ancestry and somatic profile predict acral melanoma origin and prognosis – RNA

Genomics Define Malignant Transformation in Myeloma Precursor Conditions

CcRCC_metabolic_heterogeneity

A developmental cell atlas of the human thyroid gland

Dataset for H3K27me3 ChIP-seq data for neuroblastoma cell lines (Neuroblastoma_CL)

Dataset for Transcriptomic sequencing data for neuroblastoma tumor samples

Dataset for ChIP-seq data for neuroblastoma tumor samples(NB,Neuroblastoma)

Genome and transcriptome sequence data from a recurrent odontogenic ghost cell carcinoma of the left maxilla patient

Genome and transcriptome sequence data from a breast ductal carcinoma patient

Genome and transcriptome sequence data from a melanoma patient

Genome and transcriptome sequence data from a metastatic breast carcinoma patient

Genome and transcriptome sequence data from a retroperitoneal leiomyosarcoma patient

Genome and transcriptome sequence data from a adenocarcinoma of the lung patient

Genome and transcriptome sequence data from a metastatic neuroendocrine carcinoma patient

Genome and transcriptome sequence data from a pancreatic ductal adenocarcinoma patient

Genome and transcriptome sequence data from a medullary thyroid carcinoma patient

Genome and transcriptome sequence data from a adenocarcinoma of unknown primary patient

Genome and transcriptome sequence data from a metastatic lymphoepithelial-like thymic carcinoma patient

Genome and transcriptome sequence data from a squamous cell carcinoma of unknown primary patient

Genome and transcriptome sequence data from a small cell/neuroendocrine carcinoma of the lung patient

Genome and transcriptome sequence data from a squamous cell lung carcinoma patient

Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of the esophagus patient

Genome and transcriptome sequence data from a metastatic squamous cell carcinoma of the thymus patient

Genome and transcriptome sequence data from a cholangiocarcinoma patient

Genome and transcriptome sequence data from a tongue squamous cell carcinoma (h&amp;n) patient

Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient

Genome and transcriptome sequence data from a lung adenocarcinoma patient

Genome and transcriptome sequence data from a parotid gland adenoid cystic carcinoma patient

Genome and transcriptome sequence data from a melanoma patient

Genome and transcriptome sequence data from a ewing sarcoma patient

Genome and transcriptome sequence data from a metastatic gallbladder adenocarcinoma patient

Genome and transcriptome sequence data from a lung adenocarcinoma patient

Genome and transcriptome sequence data from a metastatic pancreatic adenocarcinoma patient

Genome and transcriptome sequence data from a metastatic synovial sarcoma patient

Genome and transcriptome sequence data from a nasopharynx carcinoma patient

Genome and transcriptome sequence data from a tongue squamous cell carcinoma patient

Genome and transcriptome sequence data from a salivary carcinoma patient

Genome and transcriptome sequence data from a neuroendocrine carcinoma patient

Genome and transcriptome sequence data from a metastatic endometrioid/mucinous ovarian carcinoma patient

Genome and transcriptome sequence data from a pancreatic adenocarcinoma patient

Genome and transcriptome sequence data from a breast invasive ductal carcinoma patient

Genome and transcriptome sequence data from a metastatic ampullar carcinoma patient

Genome and transcriptome sequence data from a neuroendocrine carcinoma patient

Genome and transcriptome sequence data from a metastatic lung adenocarcinoma patient

Genome and transcriptome sequence data from a metastatic adenoid cystic carcinoma of the palate patient

Genome and transcriptome sequence data from a metastatic gastroesophageal adenocarcinoma patient

Genome and transcriptome sequence data from a metastatic adenocarcinoma of the pancreas patient

Genome and transcriptome sequence data from a metastatic paraganglioma patient

Genome and transcriptome sequence data from a salivary duct carcinoma patient

Genome and transcriptome sequence data from a tongue squamous cell carcinoma (h&n) patient